Business
Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates
HENDERSON, Nev., May 07, 2026--Zura Bio Limited (Nasdaq: ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced financial results for the first quarter ended March 31, 2026, and provided recent corporate updates.
About this update from Zura Bio Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/5b3260eef459e395b8099488f0845558"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7YN7wUUMZGWJA6._w1Qzdw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/5b3260eef459e395b8099488f0845558","width":960,"height":480},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/PBb4C20UT7tV28b12pb7Kw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTMyMA--/https://media.zenfs.com/en/business-wire.com/5b3260eef459e395b8099488f0845558","width":640,"height":320},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/FW8fvZ_m4aQT2D3WUVVTLw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0/https://media.zenfs.com/en/business-wire.com/5b3260eef459e395b8099488f0845558","width":1024,"height":512}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Continuing advancement of two Phase 2 studies evaluating tibulizumab in hidradenitis suppurativa (HS) (TibuSHIELD) and systemic sclerosis (SSc) (TibuSURE), with both trials on track to meet anticipated timelines","length":211,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Strengthened leadership team with key executive and Board appointments","length":70,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Completed an underwritten public offering in February 2026, resulting in gross proceeds of approximately $144 million to support advancement of its pipeline","length":156,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Cash and cash equivalents of $225.6 million as of March 31, 2026, which is expected to fund planned operations through at least the end of 2028","length":143,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":580,"olType":false},{"type":"text","content":"HENDERSON, Nev., May 07, 2026--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced financial results for the first quarter ended March 31, 2026, and provided recent corporate updates.","length":415,"tagNam...